spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.

With editorial consisting of in-depth articles, case studies, meetings, and report reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Advertising

Helga Schweissguth



Editorial

George Grant
 

 

 

Connect with us on Twitter: follow @EBRmagazine
   

   

>Read more publications on Calaméo

Click here to view the digital version of EBR 

 

 

 


 


Click here to view the digital version of EBR BIO-Europe Supplement

 

 

 

ebr
 
 

spacer


Published quarterly in
January, April,
July, and October


 

 
News and Press Releases

Lonza’s API Mid-Scale Manufacturing Facility Expansion in Nansha Enters Commercial Operation

Expanded capacity in Nansha, China, will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production. Capabilities add to Lonza’s integrated global manufacturing network, which maintains rigorous quality and regulatory standards around the world
More info >>

 
White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement